StockNews.AI
AMD
StockNews.AI
189 days

Intermediate AMD Epidemiology Forecast Research Report 2020-2034: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan

1. Intermediate AMD affects vision, posing risks of progression to advanced forms. 2. The US had approximately 19.8 million intermediate AMD cases in 2023. 3. An at-home monitoring program could enhance early detection of AMD progression. 4. Japan recorded 10.5 million intermediate AMD cases, expected to rise. 5. KOL insights reveal evolving therapy patterns and unmet market needs.

8m saved
Insight
Article

FAQ

Why Neutral?

Though focused on AMD, this report discusses epidemiology rather than immediate market shifts.

How important is it?

Important for understanding intermediate AMD's future market, but lacks immediate investment implications.

Why Long Term?

Insights may indicate prolonged trends in AMD treatment and patient monitoring strategies.

Related Companies

AMDNVDAINTC
Dublin, Feb. 11, 2025 (GLOBE NEWSWIRE) -- The "Intermediate AMD - Epidemiology Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.The report delivers an in-depth understanding of Intermediate AMD, historical and forecasted epidemiology of Intermediate AMD in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The intermediate AMD epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total prevalent cases of intermediate AMD, diagnosed prevalent cases of intermediate AMD, and age-specific cases of intermediate AMD in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034. AMD is a leading cause of severe vision loss in people over age 60. Intermediate AMD is a more critical distinction clinically because it places the individual at risk for progression to more advanced AMD. In early dry AMD, symptoms are minimal, and the risk of advancing is low. However, in the intermediate stage, patients often face reduced visual acuity, colour vision issues, and dark adaptation challenges, with an increased risk of progressing to geographic atrophy (GA) or wet AMD. The ForeseeHome AMD Monitoring Program by Notal Vision introduces a new option for monitoring a patient's vision at home. This at-home monitoring, offered by ForeseeHome, addresses concerns about missing the conversion from intermediate AMD to neovascular AMD. By enabling frequent monitoring for at-risk patients, it increases the chances of early detection of conversion to neovascular AMD, ultimately reducing the risk of vision loss post-conversion. Individuals 65 years of age and older account for roughly 60% of intermediate AMD prevalent cases. In 2023, the total prevalent cases of intermediate AMD in Japan were around 10,470,000 cases, and these cases are expected to increase during the forecast period. KOL ViewsTo keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the intermediate AMD evolving patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Retinal Specialist, ophthalmologist, eye specialist, and others.The analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centres such as the Institute for Saint John's Health Centre in California, Byers Eye Institute, McPherson Eye Research Institute, Department of Ophthalmology, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or intermediate AMD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs. Intermediate AMD Epidemiology Among the 7MM, the US accounted for the highest prevalent cases of intermediate AMD in 2023, with around 19,861,500 cases; these cases are expected to increase during the forecast period.Amongst EU4 and the UK, the total prevalent cases of intermediate AMD were highest in Germany, while the lowest number of cases were in Spain in 2023.According to the estimates, in Japan, it is observed that intermediate AMD was most prevalent in the 65-84 years age group, accounting for over 45% of total cases in 2023. Scope of the Report The report covers a segment of key events, an executive summary, descriptive overview of intermediate AMD, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.Comprehensive insight into the epidemiology segments and forecasts, and disease progression has been provided.The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.A detailed review of current challenges in establishing the diagnosis. Intermediate AMD Report Insights Patient PopulationCountry-wise Epidemiology DistributionAge-wise cases of intermediate AMD Intermediate AMD Report Key Strengths Eleven Years ForecastThe 7MM CoverageIntermediate AMD Epidemiology Segmentation Key Topics Covered:1. KEY INSIGHTS2. REPORT INTRODUCTION3. EXECUTIVE SUMMARY OF INTERMEDIATE AMD4. EPIDEMIOLOGY METHODOLOGY5. INTERMEDIATE AMD EPIDEMIOLOGY OVERVIEW AT A GLANCE IN THE 7MM5.1. Patient Share (%) Distribution of Intermediate AMD in 20235.2. Patient Share (%) Distribution of Intermediate AMD in 20346. DISEASE BACKGROUND AND OVERVIEW6.1. INTRODUCTION6.1.1. Classification and Clinical Manifestation6.1.2. Signs and Symptoms of AMD6.1.3. Risk Factors6.1.4. Pathophysiology of AMD6.2. Diagnosis6.2.1. Biomarkers for the Progression of Intermediate AMD6.2.2. Diagnostic Test6.3. Diagnostic Guidelines6.3.1. NICE Guidelines6.3.2. American Academy of Ophthalmology7. EPIDEMIOLOGY AND PATIENT POPULATION7.1. Key Findings7.2. Assumption and Rationale7.3. Total Prevalent Cases of Intermediate AMD in the 7MM7.4. Total Diagnosed Prevalent Cases Of Intermediate AMD in the 7MM7.5. The United States7.5.1. Total Prevalent Cases of Intermediate AMD in the US7.5.2. Total Diagnosed Prevalent Cases of Intermediate AMD in the US7.5.3. Age-specific Cases of Intermediate AMD in the United States7.6. EU4 and the UK7.6.1. Total Prevalent Cases of Intermediate AMD in EU4 and the UK7.6.2. Total Diagnosed Prevalent Cases of Intermediate AMD in EU4 and the UK7.6.3. Age-specific Cases of Intermediate AMD in EU4 and the UK7.7. Japan7.7.1. Total Prevalent Cases of Intermediate AMD in Japan7.7.2. Total Diagnosed Prevalent Cases of Intermediate AMD in Japan7.7.3. Age-specific Cases of Intermediate AMD in Japan8. AppendixFor more information about this report visit https://www.researchandmarkets.com/r/71bgbq About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Related News